UNSPSC 51332523: Moperone chlorohydrate

This classification denotes an anxiolytic with the molecular formula C22H26FNO2.ClH, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 2Z2633815T, chemically known as butyrophenone, 4'-fluoro-4-(4-hydroxy-4-p-tolylpiperidino)-, hydrochloride, but more generally known as moperone chlorohydrate, which bears US NIH Compound Identifier 4249. European Medicines Agency schedules moperone chlorohydrate or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB09057MIG.

Most nations, for tariff purposes, schedule moperone chlorohydrate under HS 29333999. SMILES: CC1CCC(CC1)C2(CCN(CC2)CCCC(=O)C3CCC(CC3)F)O.CL.

UNSPSC 51332523 Moperone chlorohydrate is a Commodity code that in practice captures state and local procurement of pharmaceutical products and drug-related medical supplies, though the recent opportunities indexed under it diverge significantly from the code's nominal scope. State and local governments are actively soliciting naloxone and drug deactivation systems, generic multi-source pharmaceuticals, over-the-counter products, and direct-to-manufacturer prescription programs through this code. The issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances; Seminole County, Florida; the Texas Health and Human Services Commission; and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) have posted opportunities in the past four months. Solicitations require vendors to meet FDA compliance, cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, E-Verify requirements, and comprehensive insurance coverage including workers' compensation, general liability, and professional liability.

Recent activity is concentrated in Florida, Texas, and Minnesota. Seminole County issued IFB60459723LAS on June 30, 2026 (due July 26, 2023, with a likely date discrepancy in the source) for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries to Sanford, Florida and a two-year initial term with one-year renewal option on a fixed-fee basis. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026 as a market-intelligence solicitation regarding direct-to-manufacturer prescription programs for self-insured employer health plans and state agencies. MMCAP issued RFP S1070000015802 on January 20, 2026 (response due March 26, 2026) for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers to state and local government facilities across participating states including Oregon, with pricing weighted 75 percent and compliance, EDI capability, and administrative requirements accounting for the remainder. Vendors must maintain contractual relationships with at least two of three named wholesalers and comply with a 3 percent administrative fee structure.